// App-Quantinova.ai

AB0370 (2021) : UTILITY OF CRP AND ESR IN THE DIAGNOSIS OF GIANT CELL ARTERITIS RELAPSE IN A PHASE 2 TRIAL OF MAVRILIMUMAB

Researchers

Presenter

  • S. Unizony

Principal Investigators

  • M. C. Cid

  • E. Brouwer

  • L. Dagna

  • B. Dasgupta

  • B. Hellmich

  • E. Molloy

  • C. Salvarani

  • B. C. Trapnell

  • K. J. Warrington

  • I. Wicks

  • M. Samant

  • T. Zhou

  • L. Pupim

  • J. F. Paolini

Medical Centers

  • Massachusetts General Hospital, Vasculitis and Glomerulonephritis Center, Department of Rheumatology, Allergy and Immunology, Boston, United States of America

  • Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Vasculitis Research Unit, Department of Autoimmune Diseases, Barcelona, Spain

  • University of Groningen, University Medical Center, University of Groningen, University Medical Center, Groningen, Netherlands

  • San Rafael Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milano, Italy

  • Vita-Salute San Raffaele University, Vita-Salute San Raffaele University, Milan, Italy

  • Southend University Hospital NHS Foundation Trust, Southend University Hospital NHS Foundation Trust, Westcliff-on-sea, United Kingdom

  • Medius Kliniken, Department of Internal Medicine, Rheumatology, and Immunology, Kirchhelm unter Teck, Germany

  • St Vincent’s University Hospital, St Vincent’s University Hospital, Dublin, Ireland

  • Arcispedale Santa Maria Nuova, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

  • Cincinnati Children’s Hospital, Translational Pulmonary Science Center, Cincinnati, United States of America

  • Mayo Clinic and Mayo Foundation, Rochester, United States of America

  • Walter & Eliza Hall Institute & Melbourne Health, Walter & Eliza Hall Institute & Melbourne Health, Melbourne, Australia

  • Kiniksa Pharmaceuticals Corp., Clinical Development, Lexington, United States of America

Locations

  • United States

  • Spain

  • Netherlands

  • Italy

  • United Kingdom

  • Germany

  • Ireland

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

Disease

  • Giant cell arteritis

Biomarkers

  • C reactive protein

  • Estrogen receptor alpha

Drug/Treatment

  • Mavrilimumab

  • Prednisone

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Genentech

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved